Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today ...
USA Today

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

Canalevia ® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs Jaguar is exploring the ...
The News-Press

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia’s Indication to Treatment of General Diarrhea in Dogs

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatment of CID in dogs Company strategy: In discussions with multiple ...